Down 27% from Oct 21 to Oct 30 while the S&P 500 fell 2%.
−2Volatility
Follow INBX's trial news. Pro members can get an alert when Inhibrx Biosciences files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 9.9% a day with no profit behind it |
| Latest filing | 10-Q, Aug 13 |
Thu Nov 19: Connective Tissue Oncology Society…Industry event · date confirmed.
After its last 4 reports it closed -3.9% on average, higher 1 of 4 times.
About 4 quarters
No shelf registration or at-the-market program on file in the last three years.
CEO Mark Lappe bought 10,040 shares on Oct 14. 8 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
INBX is #133 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 133 |
Reports Fri Nov 13, after the close (in 11 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase is primarily due to higher interest expense on the Company's $175.0 million outstanding loan balance during the second quarter of 2026 as compared to $100.0 million outstanding during the second quarter of 2025.”
INBX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 13, 2026 | -5.4% | -8.9% | +2.2% |
| May 14, 2026 | +2.1% | -6.5% | -4.8% |
| Mar 19, 2026 | -1.5% | -6.1% | +1.4% |
Sales grew in one of the last two years, to $1.3M in 2025. It lost money in 2025 after a profit in 2024.
3 insiders bought $6.3M across 19 filings, and one insider sold $279K across 5 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: INBX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
“The biopharmaceutical industry is characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property.”
INBX scores 0 today, which Breakaway calls Below Average. It is #133 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 27% from Oct 21 to Oct 30 while the S&P 500 fell 2%. Cash lasts about 4 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
INBX scores 0 today, which Breakaway calls Below Average (0 to 5). That is #133 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind INBX's 0.
3 insiders bought $6.3M across 19 filings, and one insider sold $279K across 5 filings, in the last 6 months. The newest is Mark Lappe, Chief Executive Officer, who bought $210K on Oct 14. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.